S3. Rituximab for ANCA-associated vasculitides: the French experience

MeSH terms

• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
• Antibodies, Antineutrophil Cytoplasmic / blood
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / therapeutic use
• Antibodies, Monoclonal, Murine-Derived / adverse effects
• Antibodies, Monoclonal, Murine-Derived / therapeutic use*
• Cyclophosphamide / adverse effects
• Cyclophosphamide / therapeutic use
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• France
• Granulomatosis with Polyangiitis / drug therapy
• Granulomatosis with Polyangiitis / immunology
• Humans
• Immunologic Factors / adverse effects
• Immunologic Factors / therapeutic use*
• Immunosuppressive Agents / therapeutic use
• Infliximab
• Prospective Studies
• Randomized Controlled Trials as Topic
• Retrospective Studies
• Rituximab
• Treatment Outcome